All In Biotech

Drug Trial Radar · NCT07527910

A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD

A Two-Part, Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study of ALN-PNP With and Without a GLP1R Agonist in Adults With Homozygous PNPLA3-Related Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 204 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

204

Planned (sponsor's estimate)

Start

May 22, 2026

Primary completion

Mar 15, 2030

Study completion Mar 15, 2030

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Apr 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will test a study drug called ALN-PNP with and without another drug that is used for controlling blood sugar, appetite, and weight (for example, tirzepatide), to see if it can help treat MASLD, also known as fatty liver disease. ALN-PNP reduces the amount of Patatin-like phospholipase domain-containing protein 3 (PNPLA3), a protein that liver cells make, which may help decrease liver fat if there is an abnormal PNPLA3 protein. The goal of this study is to understand the effect of ALN-PNP with or without tirzepatide on reducing liver fat. The study is looking at: * How well ALN-PNP with and without tirzepatide works * What side effects ALN-PNP might cause * How much ALN-PNP is in the blood at different times * How the body and the liver change after having ALN-PNP, which can help researchers understand why ALN-PNP works better in some people than others

Conditions

  • Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Interventions

  • ALN-PNPDrug

    Administered per the protocol

  • TirzepatideDrug

    Administered per the protocol

  • PlaceboDrug

    Administered per the protocol Placebo matching ALN-PNP

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change in liver fatTime frame: From baseline at week 24
  2. Percent change in liver fatTime frame: From baseline at week 48

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Arizona Liver Health - Tucson

    Tucson, Arizona · Recruiting

  • Southern California Research Center

    Coronado, California · Recruiting

  • California Liver Research Institute

    Pasadena, California · Recruiting

  • Health Awareness - Jupiter

    Jupiter, Florida · Recruiting

  • Evolution Clinical Trials

    Miami, Florida · Recruiting

  • Tandem Clinical Research, Plaza II

    Metairie, Louisiana · Recruiting

  • Geisinger Medical Center

    Danville, Pennsylvania · Recruiting

  • American Research Corporation

    Austin, Texas · Recruiting

  • Advanced Medical Trials

    Georgetown, Texas · Recruiting

  • American Research Corporation at The Texas Liver Institute

    San Antonio, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.